Best Neurology Companies in Texas, United States
The 61 best Neurology companies in Texas, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Taysha Gene Therapies.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Texas
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Taysha Gene Therapies Developer of gene-based therapies for treating CNS disorders | $125M | 34 mo ago | 183 183 → 134 (-27%) | R.A. Session Founder & CEO | Public | — | — |
| 2 | MicroTransponder Developer of neuromodulation therapy for neurological conditions | $115M | 16 mo ago | 33 | Jordan Curnes Co-Founder & President | Series F | 87 patents Vagus nerve stimulation integrated with motor and therapeutic rehabilitation devices | — |
| 3 | NEOS Therapeutics Speciality Company developing extended release drugs for CNS disorders using proprietary technology platform | $95M | 121 mo ago | 150 | Michael Young Farvo Founder And Chairman Of The Board | Public | — | — |
| 4 | IntraBio Developer of therapies for treating rare and neurodegenerative diseases | $60M | 32 mo ago | 4 | — | Series C | 6 patents Therapeutic use of N‑acetyl‑leucine for rare neurodegenerative and lysosomal disorders | — |
| 5 | XCath Developer of endovascular robotics and steerable guidewires 45Innovation top 23%Patents top 26%Funding top 28%Moat top 28% All 7 signals ▾Innovationtop 23% Patentstop 26% Fundingtop 28% Moattop 28% Talentbottom 49% Globalbottom 40% Marketbottom 24% Innovation: 128 patents (top 15% of patent-holders) · 72 filings since 2022 vs 56 in 2017-21 Patents: 128 patents matched (strict assignee match) · 72 filings since 2022 vs 56 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $30M | 3 mo ago | 10 | Eduardo Fonseca CEO | Series C | 128 patents Patents concentrated in health & consumer products | — |
| 6 | Cassava Sciences Developer of small molecule-based therapeutic solutions for treating neurological diseases | $27M | 61 mo ago | 24 | Remi Barbier CEO & President | Public | — | — |
| 7 | Vaxxinity Developer of vaccines for neurological disorders and infectious diseases | $27M | 63 mo ago | 92 | — | Public | 34 patents Peptide immunotherapy targeting tau, amyloid‑beta and synuclein in neurodegenerative diseases | — |
| 8 | CNS Pharmaceuticals Developer of treatments for primary and metastatic cancers in the brain and central nervous system 42Funding top 23%News top 23%Growth top 25%Talent top 43% All 7 signals ▾Fundingtop 23% Newstop 23% Growthtop 25% Talenttop 43% Techbottom 45% Globalbottom 43% Marketbottom 19% Funding: Raised $22.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 6 BI events in 12 mo (of 33 tracked, 7 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 42/100 | $23M | 2 mo ago | 5 | John Climaco CEO | Public | — | 1 job opening |
| 9 | Coya Therapeutics Developer of therapeutics for cell therapy and exosome therapy | $20M | 20 mo ago | 6 | — | Public | — | — |
| 10 | Vapogenix Developer of topical, non-opioid analgesics to alleviate pain | $19M | 67 mo ago | 5 | Phillip Phan Co-Founder | Series C | 54 patents Pain‑relief drug formulations using halogenated volatile compounds for analgesic therapy. | — |
| 11 | Motif neurotech Developer of minimally invasive bioelectronics for mental health disorders | $19M | 29 mo ago | 7 | Jacob Robinson Co-Founder & CEO | Series A | 8 patents Closed-loop neural interfaces using implantable magnetoelectric stimulation and wireless monitoring | 1 partnership |
| 12 | Spark Biomedical Developer of wearable neurostimulation technology for drug-free opioid withdrawal treatment 53Patents top 23%Innovation top 26%Funding top 32%Moat top 38% All 10 signals ▾Patentstop 23% Innovationtop 26% Fundingtop 32% Moattop 38% Techtop 40% Growthtop 45% Talentbottom 49% Productbottom 48% Globalbottom 40% Marketbottom 29% Patents: 61 patents matched (strict assignee match) · 55 filings since 2022 vs 6 in 2017-21 Innovation: 61 patents (top 27% of patent-holders) · 55 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $16M | 10 mo ago | 18 18 → 27 (+50%) | Daniel Powell CEO | Series A | 61 patents Non‑invasive auricular neurostimulation devices for women's health therapies | 1 award |
| 13 | Phoenix Biotechnology Develops plant based therapies for treatment of cancer | $13M | 70 mo ago | 7 | — | Series B | 207 patents Pharmaceutical formulations targeting viral infections, skin disorders, and glioblastoma cancer therapies. | — |
| 14 | Cersci Therapeutics Global technology company providing cutting-edge solutions for the ready-mix concrete industry | $12M | 75 mo ago | 17 | — | Acquired | — | — |
| 15 | Amprion Revolutionizing neurodegenerative disease diagnosis with advanced α-synuclein detection technology | $12M | 20 mo ago | 34 34 → 37 (+9%) | Russ Lebovitz CEO | Series B | 95 patents Protein misfolding detection assays for neurodegenerative disease biomarkers | — |
| 16 | Diakonos Provider of immunotherapeutics for cancer treatment | $11M | 13 mo ago | — | Mike Wicks CEO | Seed | — | 1 partnership |
| 17 | Alzeca Developing advanced imaging agents for early diagnosis of neurodegenerative diseases | $11M | 106 mo ago | 4 | — | Series A | — | — |
| 18 | VISIE Provider of 3D intraoperative imaging technology for orthopedic, neuro, and spine surgery 42Talent top 28%Innovation top 30%Patents top 32%Funding top 36% All 8 signals ▾Talenttop 28% Innovationtop 30% Patentstop 32% Fundingtop 36% Moattop 38% Techbottom 44% Globalbottom 36% Marketbottom 25% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Innovation: 17 patents (top 49% of patent-holders) · 17 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $10M | 14 mo ago | — | Aaron Bernstein Co-Founder & CTO | Series A | 17 patents Patents concentrated in computing, sensing & instrumentation | — |
| 19 | Renovo Concepts Developer of a mechanical tissue resuscitation system for the treatment of traumatic, ischemic, and… | $9M | 38 mo ago | 5 | Charles Biltz Co-Founder | Series A | 9 patents Patents concentrated in health & consumer products | — |
| 20 | Invictus Medical Innovating NICU environments, improving newborn lives through noise reduction technology | $9M | 94 mo ago | 5 | George Hutchinson Chief Executive Officer | Series A | — | — |
| 21 | Curtana Pharma US-based, early-stage biopharma developing transcription factor targeting small molecule therapeutics for… | $8M | 109 mo ago | 5 | Gregory Stein Co-founder | Seed | — | — |
| 22 | Autonomix Developer of minimally invasive neural monitoring and treatment devices | $8M | 37 mo ago | 4 | Robert Schwartz Co-Founder | Public | — | 1 launch |
| 23 | GenrAb Developer of neuroprotective monoclonal antibodies for treating neurological disorders | $6M | 14 mo ago | — | Larry Tiffany CEO | Seed | — | — |
| 24 | Neurolink Drug-device combination for epilepsy | $4M | 185 mo ago | 15 | Phil Morgan CEO & President | Deadpooled | — | — |
| 25 | Statera Spine Provides software to enable the imaging analytics for spine disorders | $4M | 82 mo ago | 24 | — | Acquired | — | — |
| 26 | Cx Precision Medicine Developer of blood-based biomarker screening technology, diagnostics, and other | $2M | 42 mo ago | 3 | Danguole Altman President and CEO | Seed | 65 patents Patents concentrated in chemistry & materials | — |
| 27 | 4E Therapeutics Developer of drugs for treating neuropathic pain | $2M | 55 mo ago | 6 | Joe Price Co-Founder & President | Seed | 1,883 patents Targeted protein degraders (PROTACs) and exosome therapeutics for oncology and neurodegeneration | — |
| 28 | NeuroChaos Solutions Navigating neurodiversity in life and marriage with ADHD and dyslexia | $2M | 122 mo ago | — | Patrick Kothe Co-Founder & CEO | Seed | — | — |
| 29 | Covalent Bioscience Developer of nature-made catalytic antibodies for therapeutic and vaccine applications | $1M | 178 mo ago | 3 | Sudhir Paul Co-Founder | Funding Raised | — | — |
| 30 | EyeGuide Provider of a concussion detection solution through eye-tracking | $1M | 36 mo ago | 4 | Patrick Carney CEO | Seed | 14 patents Eye-tracking based cognitive assessment devices and software for neurological testing | — |
| 31 | Frontier Toxicology Diagnostics company offering customized toxicology services for physicians practices | $695K | 160 mo ago | 6 | W. Wade White CEO | Deadpooled | — | — |
| 32 | ReEngage Developer of therapeutics for longevity-related diseases | $365K | 12 mo ago | — | Gottlieb Co-Founder | Seed | — | 1 partnership |
| 33 | Opsin Biotherapeutics Developer of gene therapies for the treatment of chronic pain | $328K | 35 mo ago | — | Robert Benkowski CEO and Co-founder | Funding Raised | — | — |
Top 12 Neurology companies in Texas
#1
Public · Houston, Texas · founded 2017 · 5 employees$22.5Mraised▾
Developer of treatments for primary and metastatic cancers in the brain and central nervous system. It offers a pipeline of anti-cancer drug candidates including berubicin that appears to cross the blood brain barrier and kill tumor cells and TPI 287 for glioblastoma multiforme.
- May 2026Series B$22.5M
#2
Series C · Houston, Texas · founded 2017 · 10 employees$30Mraised▾
Developer of endovascular robotics and steerable guidewires. The company is developing robotic systems that can enable expert navigation of the body's complex vascular network to treat life-threatening conditions like cerebrovascular disorders.
- Mar 2026Series C$30M
#3
Series F · Dallas, Texas · founded 2007 · 33 employees$115.4Mraised▾
Developer of neuromodulation therapy for neurological conditions. The company uses proprietary technology and product- microtransponder's product is the Vivistim Paired VNS System, for helping stroke survivors regain upper limb motor function after their stroke.
- Mar 2025Series F$65M
- Jun 2022Series E$73M
- Sep 2020Conventional Debt$5.8M
- Nov 2017Series C$11.6M
#4
Series A · Houston, Texas · founded 2018 · 18 employees$16.2Mraised▾
Developer of wearable neurostimulation technology for drug-free opioid withdrawal treatment. The company provides non-invasive bioelectric medicine designed to meet critical needs. Their current FDA-cleared neurostimulation solution is for opioid withdrawal. The technology is also evolving into neurological health, hemostasis, and pediatrics.
- Aug 2025Grant (prize money)—
- Apr 2025Series A$15M
- Jun 2024Grant (prize money)$318.9K
- May 2023Series A$16.2M
#5
Series A · Austin, Texas · founded 2017$9.7Mraised▾
Provider of 3D intraoperative imaging technology for orthopedic, neuro, and spine surgery. The company's proprietary maging hardware combines the power of science and deep tech to develop intraoperative scanners to streamline surgeries in the operating room.
- Apr 2025Series A$3M
- Nov 2023Series A$8.2M
- Feb 2021Series A—
- Aug 2020Series A—
#6
Seed · Houston, Texas · founded 2022$11.4Mraised▾
Provider of immunotherapeutics for cancer treatment. It offers Dendritic Cell Vaccines for Glioblastoma, Pancreatic cancer, Sarcoma, Intratumoral Injection for Bone Cancer, Head and Neck Cancer, and CAR T cell therapies for HER 2+ Breast Cancer, and solid tumors.
- Jun 2025Seed$20M
- Aug 2024Seed$11.4M
#7
Public · Houston, Texas · founded 2020 · 6 employees$20.4Mraised▾
Developer of therapeutics for cell therapy and exosome therapy. The company developed various products such as ALS 001 and EXO 001 for Amyotrophic Lateral Sclerosis, FTD 080 and EXO O50 for Frontotemporal Dementia, and AID 912 for Scleroderma.
- Oct 2024Post IPO$10M
- May 2024Post IPO$5M
- Dec 2023Post IPO$26.5M
- May 2022Series A$10.4M
#8
Series B · Houston, Texas · founded 2006 · 34 employees$11.8Mraised▾
Revolutionizing neurodegenerative disease diagnosis with advanced α-synuclein detection technology. They offer innovative diagnostic solutions for neurodegenerative disorders, providing clinicians and biopharma companies with tools for accurate and early detection. Their core technology, SAAmplify, detects misfolded α-synuclein, aiding in the diagnosis of diseases like Parkinson’s, Lewy body dementia, and Alzheimer’s. This technology moves beyond symptom-based diagnosis, offering biological clarity for improved treatment decisions. They provide resources, clinical studies, and testing services to support patients, clinicians, and researchers. Their mission is to impact lives by identifying diseases early, minimizing brain damage. They offer a test for detecting synucleinopathies before symptoms progress, identifying mixed pathologies for improved care. They partner with biopharma to accelerate clinical trials, stratify patients, and monitor treatment efficacy. They provide access to expertise and technology for advancing neurodegenerative science.
- Oct 2024Series B$6M
- Sep 2024Grant (prize money)$100K
- Sep 2024Series A$5.8M
- Apr 2018Grant (prize money)$1.5M
#9
Seed · Dallas, Texas · founded 2022$5.6Mraised▾
Developer of neuroprotective monoclonal antibodies for treating neurological disorders. It focuses on developing therapies that protect and treat patients with neurological diseases. The company's proprietary Antibody Gene Signature (AGS) technology identifies potentially therapeutic fully-human mAbs to treat neurological disorders. These antibodies leverage naturally created neuroprotective mechanisms found in individuals experiencing neurodegeneration. The company aims to prevent disease progression and provide neuroprotection.
- Apr 2025Seed$5.6M
#10
Public · Dallas, Texas · founded 2020 · 183 employees$125Mraised▾
Developer of gene-based therapies for treating CNS disorders. The company has developed an AAV9 capsid delivery system and Zolgensma is a gene-based therapy to treat CNS diseases. The pipeline includes TGTX-104, gene replacement therapy to treat Rett Syndrome (IND enabling), TGTX-106, short hairpin RNA, to treat Angelman, and more.
- Aug 2023Post IPO$150M
- Oct 2022Post IPO$50M
- Aug 2020Series B$95M
- May 2020Seed$30M
#11
Series C · Austin, Texas · founded 2015 · 4 employees$60.2Mraised▾
Developer of therapies for treating rare and neurodegenerative diseases. The lead compound IB1001 is a small molecule, which modulates lysosomal function and it normalizes the intracellular ion regulation via calcium channels to treat orphan indications such as GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) and Ataxia-Telangiectasia. It also offer AQNEURSA (levacetylleucine) is indicated for the treatment of neurological manifestations of Niemann-Pick disease.
- Nov 2023Series C$40.3M
- Apr 2023Series C$15M
- Jan 2018Series B$4.9M
#12
Series A · Houston, Texas · founded 2022 · 7 employees$18.8Mraised▾
Developer of minimally invasive bioelectronics for mental health disorders. It offers a miniature brain pacemaker that stimulate the brain to restore healthy circuit activity and treat mental health disorders like treatment resistant depression.
- Jan 2024Series A$18.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
How research on Neurotech in Texas is moving
A read on the academic research around Neurotech in Texas — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 301 papers.
UT Southwestern and UT Dallas lead Texas neurotech research, focusing optimistically on neurological disorder treatments, neural engineering, and BCI development, with Parkinson's mechanisms as a dominant clinical theme.
- The University of Texas Southwestern Medical Center80
- The University of Texas Health Science Center at Houston58
- The University of Texas at Dallas31
- Texas Children\'s Hospital27
- The University of Texas at Austin20
- Deep brain stimulation3→14
- Neuromodulation1→9
- Neuroprosthetics1→6
- Brain–computer interface1→4
- Neuroscience8→11
- Deep brain stimulation14→35
- Stimulation4→19
- Neuromodulation3→15
- Neuroscience13→24
- Neurostimulation5→15
- Neurostimulation1→9
- Neuromodulation1→4
- Transcranial magnetic stimulation1→3
- Brain stimulation3→4
- Stimulation2→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.